SeekInCure®
The first-in-class blood-based pan-cancer recurrence monitoring test
SeekInCure® is applied to monitoring cancer recurrence and risk evaluation for post-op cancer patients. By monitoring the variation of cancer genome in cell-free DNA (cfDNA) of post-op cancer patients continually, combined with plasma protein markers, equipping big data and artificial intelligence, it generates cancer recurrence index (CRI) .
A panoramic view of cancer genomic landscape
cfDNA detection via NGS drawing the view of cancer genomic landscape
Cutting-edge multivariate algorithm
Genomics combined with proteomics，capturing the signal of cancer recurrence
Multidimensional fingerprint
CNA, Fragmentation and protein markers discovering the early cancer recurrence
Big date and Artificial intelligence
CRI model based on machine learning evaluating the risk of cancer recurrence precisely
Specifications
◉ Indicated subjects: post-surgery cancer patients
◉ Sample requirement: 10ml peripheral blood
◉ Result readout: CRI (cancer recurrence index)
◉ TAT: 10 working days
◉ Sampling time:
粤公网安备 44030802000447号所有文章
×